Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Snake venom protein could prevent blood clots
Researchers found that a protein derived from the venom of the tropidolaemus wagleri snake reduced the formation of blood clots in mice.

Discovery could lead to safer treatment for blood clots

A protein found in snake venom could lead to a safer treatment for blood clots, new research has found.

According to Medical News Today, a protein derived from the venom of the tropidolaemus wagleri snake has reduced the formation of blood clots in mice, without excessive bleeding.

The research was carried out by National Taiwan University in Taipei and published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology.

Current methods for reducing the formation of blood clots - such as aspirin and clopidogrel - work by preventing platelets from clumping together. Doctors prescribe these antiplatelet medications to prevent heart attack, stroke and heart disease, but a major side effect is bleeding after an injury.

It is hoped that this new discovery could pave the way to a new antiplatelet drug that is equally effective, but not cause excessive bleeding.

Trowaglerix

In previous studies, researchers found that that trowaglerx - a protein found in the venom of tropidolaemus wagleri - interacts with glycoprotein VI (GPVI) - a protein that resides on the surface of platelets - to form blood clots.

In this new study, Dr Jane Tseng and her colleagues assessed the structure of this protein and were able to create a drug that blocks GPVI activity.

When they tested the drug on mice, the mice experienced slower blood clot formation. They also didn’t bleed any longer than mice that hadn’t been treated with the drug.

Dr Tseng believes the findings suggest that trowaglerix might offer a safer, effective strategy to prevent blood clots. But she stresses that more research is needed to ascertain the safety and efficacy of the drug in humans.

"In general, this type of molecule design does not last long in the body, so techniques like formulation or delivery system are likely needed to extend the exposure time in the human body," she told Medical News Today.

“The design must also be optimised to ensure that the molecule only interacts with GPVI and not other proteins which can cause unintended reactions."

Image (C) gbohne.

Become a member or log in to add this story to your CPD history

Survey seeks to learn about racehorse aftercare

News Story 1
 The British Horseracing Authority (BHA) is launching a survey to improve understanding of aftercare for thoroughbreds. The survey has been emailed to trainers, who are asked to share their own experiences, with a focus on life after horses finish their racing careers. It forms part of an equine health and welfare strategy being developed by the BHA. 

News Shorts
BEVA launches programme to support new equine vets

A new series of courses is aiming to help those in the early stages of an equine veterinary career. The BEVA’s Equine Practice Fundamentals Programme is comprised of 10 CPD courses on the essentials of equine care, with a mixture of lectures and hands-on practicals.

The BEVA said it is aware from younger vets and employers that there are some equine fields where newer graduates are lacking in clinical skills. The course, which has been designed following consultation with over 60 senior practitioners across BEVA’s membership, will run in 2018 and 2019. For further information visit: www.beva.org.uk